Skip to main content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.covid19.nih.gov

Grant Details

Grant Number: 5R03CA088180-02 Interpret this number
Primary Investigator: Helzlsouer, Kathy
Organization: Johns Hopkins University
Project Title: Epidemiology of Prostate Cancer-Odc and AR Genotypes
Fiscal Year: 2001


Abstract

In keeping with the NCI initiative to stimulate innovative molecular epidemiologic research into the origins and progression of prostate cancer we plan to focus on the association between a new polymorphism found on the ornithine decarboxylase gene (ODC) and the development of prostate cancer. Ornithine Decarboxylase (ODC) is an enzyme in the polyamine biosynthetic pathway responsible for cellular proliferation and differentiation. Overexpression of ODC has been shown to predispose to both tumor growth and progression. We also plan to explore whether the association between the ODC genotype and the risk of prostate cancer varies by the presence of a polymorphism of the androgen receptor gene. This nested case-control study will be conducted using pre- diagnostic blood collected in 1989 as well as information on two separate questionnaires collected from men in Washington County in 1989 and 1996 as part of a large ongoing prospective study. 164 cases who have developed prostate cancer will be compared with 323 controls that are matched on age, gender and were free of other cancers at the time of diagnosis of the case. From the point of view of etiology, findings will aid in the understanding of inherited factors that influence tumor growth and progression in men with prostate cancer. From the point of view of prevention, we may be able to isolate a group of men that are at a higher risk of developing prostate cancer and possibly modify this risk by using drugs such as alpha- difluoromethylornithine (DFMO) or green tea that have been shown to inhibit ornithine decarboxylase.



Publications

Differences in ornithine decarboxylase and androgen receptor allele frequencies among ethnic groups.
Authors: O'Brien T.G. , Guo Y. , Visvanathan K. , Sciulli J. , McLaine M. , Helzlsouer K.J. , Watkins-Bruner D. .
Source: Molecular carcinogenesis, 2004 Oct; 41(2), p. 120-123.
PMID: 15378650
Related Citations

Association among an ornithine decarboxylase polymorphism, androgen receptor gene (CAG) repeat length and prostate cancer risk.
Authors: Visvanathan K. , Helzlsouer K.J. , Boorman D.W. , Strickland P.T. , Hoffman S.C. , Comstock G.W. , O'Brien T.G. , Guo Y. .
Source: The Journal of urology, 2004 Feb; 171(2 Pt 1), p. 652-5.
PMID: 14713779
Related Citations

Automated fragment analysis method for determining androgen receptor CAG repeat length.
Authors: Boorman D.W. , Guo Y. , Visvanathan K. , Helzlsouer K. , O'Brien T.G. .
Source: BioTechniques, 2002 Jul; 33(1), p. 140-3.
PMID: 12139238
Related Citations




Back to Top